1ST Biotherapeutics Inks ~$314.8M Deal with SK Biopharmaceuticals for 1ST-104

Shots: 1ST Biotherapeutics SK Biopharmaceuticals have entered into an exclusive global licensing agreement & strategic equity investment partnership to advance 1ST-104 for the treatment of Parkinson’s disease  As per the deal, 1STBIO will receive a $1.8M upfront payment, with the licensing agreement valued at ~$314.8M, incl. a $1.8M short-term milestone upon candidate selection & additional milestones Upon commercialization, 1STBIO will receive tiered royalties on global net sales, while SKBP has made a $2.2M strategic equity investment in 1STBIO to support a long-term partnership Ref: PRnewswire |  Image: 1ST Biotherapeutics SK Biopharmaceuticals  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post 1ST Biotherapeutics Inks ~$314.8M Deal with SK Biopharmaceuticals for 1ST-104 appeared first on PharmaShots.